News & Updates
Filter by Specialty:
Upadacitinib provides robust, long-term control of moderate-to-severe AD
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Upadacitinib provides robust, long-term control of moderate-to-severe AD
23 May 2022
Different booster shot strengthens immune response against Omicron
Getting a different type of mRNA vaccine for the booster shot leads to a stronger neutralizing immune response against the COVID-19 Omicron variant, according to a recent Singapore study.
Different booster shot strengthens immune response against Omicron
23 May 2022
Cancer patients more vulnerable to PTSD during pandemic
Cancer patients may be more susceptible to developing symptoms of post-traumatic stress disorder (PTSD), especially amid the COVID-19 pandemic, reports a recent study.
Cancer patients more vulnerable to PTSD during pandemic
23 May 2022
Keto diet: Is there good evidence in MS?
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Keto diet: Is there good evidence in MS?
23 May 2022
Which canagliflozin dose is best for T2DM patients with hypertension?
A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.